Alzheimer' s is a complex disease and there is no single "magic bullet"
available in the market to prevent or cure it. Though many marketed drugs have
been approved for Alzheimer' s disease, but it still remains a significant area
of unmet medical need. Clinical success has proven elusive; however, numerous
companies are developing novel treatments. Currently there' s no cure for
Alzheimer' s and its still waiting for its key product. In addition, all
current marketed products are going to be generic in the next five years.
In 2010, there were more than 30 Million people suffering with Alzheimer' s
disease but it is anticipated that by 2015 over 35 Million people worldwide
will be suffering from this disease. Much of this increase will be due to
increase in number of people with Alzheimer' s in low and middle income
countries. Since the risk of getting the disease increases with age, the
number of patients with the illness to be found in any community will depend
on the proportion of older people in the group. Traditionally, the developed
countries have large proportions of elderly people, and so they have many
cases of Alzheimer' s disease in the community at one time. However, developing
countries are also undergoing a demographic transition so that more and more
persons are surviving to an old age.
Global Alzheimer' s disease has increased manifold and expected to cross US$ 19
Billion by 2015. North America controls more than 50% of the total Alzheimer' s
drug market share in 2010. Over the past years, the Alzheimer' s disease market
has been flagged with several drugs into the market. Till last year Aricept
was the world best selling drug which lost patent protection in November 2010,
a milestone that will be followed by a rapid loss in sales. But there are
other drugs which has the potential to become blockbuster drug by 2010.
Namenda, Exelon has shown alluring growth in the market and become
blockbusters in 2010. Ebixa a drug of Memantine group is expected to have a
Billion dollar market by 2014. Given the alarming worldwide growth in
Alzheimer' s patients, and especially if companies are able to address major
unmet needs, the outlook for the Alzheimer' s disease market is excellent.
Renub Research report titled "Alzheimer' s Disease Patients & Market Worldwide,
Future Scenario (2010 - 2015) & Drugs Analysis" studies the Alzheimer' s
Disease patients prevalence worldwide and region wise. The report provides
data on the Alzheimer' s Disease market Worldwide, North America, Europe and
Rest of the world.
Alzheimer' s drugs such as Exelon, Aricept, Namenda, Razadyne, Axura, Ebixa,
Nootropil, Prometax, Memac, Eranz market past, present and future scenario has
been analyzed in this report.
Key questions answered in the report?
Which regions have the highest prevalence of Alzheimer' s Disease diseases
today and by 2050?
What is the market share accounted by Alzheimer' s disease drugs in the
What is the market share accounted by the region in the global market?
Which drugs have patent expiry and future forecast of drug sales?
More than 35 Million people are expected to suffer from Alzheimer' s
disease by 2015 worldwide.
By 2050, 59 percent of the world' s Alzheimer' s cases will live in Asia.
Global Alzheimer' s disease market is expected to cross the figure of US$
19 Billion by 2015.
North America is the leading market share taker in the Alzheimer' s disease
Aricept sales is expected to fall after losing its patent in November 2010
Ebixa, Excelon & Namenda are on the path of becoming the next blockbuster
drugs after Aricept
Key Company Profiles
This section provides business overview and key financial information of the
companies listed below: Forest Laboratories, Eisai, H. Lundbeck A/S, Novartis,
Merz GmbH & Co. KGaA, Johnson & Johnson, UCB
Information and data in this report has been collected from various printable
and non-printable sources like Trade Journals, White papers, Online paid
databases, News websites, Government Agencies, Magazines, Newspapers and Trade
Table of Contents
1. Executive Summary
2. Worldwide Prevalence of Alzheimer' s Patients
2.1 Total Number of Alzheimer' s Patients
2.2 Total Number of Early Stage Alzheimer' s Patients
2.3 Total Number of Late Stage Alzheimer' s Patients
3. Regional Estimates for Alzheimer' s Patients
3.1.1 Total Number of Alzheimer' s Patients
3.1.2 Total Number of Early Stage Alzheimer' s Patients
3.1.3 Total Number of Late Stage Alzheimer' s Patients
3.2.1 Total Number of Alzheimer' s Patients
3.2.2 Total Number of Early Stage Alzheimer' s Patients
3.2.3 Total Number of Late Stage Alzheimer' s Patients
3.3.1 Total Number of Alzheimer' s Patients
3.3.2 Total Number of Early Stage Alzheimer' s Patients
3.3.3 Total Number Of Late Stage Alzheimer' s Patients
3.4 Latin America & Caribbean
3.4.1 Total Number of Alzheimer' s Patients
3.4.2 Total Number of Early Stage Alzheimer' s Patients
3.4.3 Total Number of Late Stage Alzheimer' s Patients
3.5 North America
3.5.1 Total Number of Alzheimer' s Patients
3.5.2 Total Number of Early Stage Alzheimer' s Patients
3.5.3 Total Number of Late Stage Alzheimer' s Patients
3.6.1 Total Number of Alzheimer' s Patients
3.6.2 Total Number of Early Stage Alzheimer' s Patients
3.6.3 Total Number of Late Stage Alzheimer' s Patients
4. Worldwide Alzheimer' s Disease Market
4.1 North America Alzheimer' s Disease Market
4.2 Europe Alzheimer' s Disease Market
4.3 Rest of the World Alzheimer' s Disease Market
5. Worldwide - Alzheimer' s Drug Market Share 2008 - 2009
6. Worldwide - Top 10 Alzheimer' s Drug Brands Market Performance